Business Wire

FoodChain ID Certifies Mulino Bianco’s Buongrano to Regenerative Agriculture (RGN) Standard

Share

FoodChain ID today announced that Mulino Bianco’s Buongrano has been certified to the FoodChain ID Regenerative Agriculture (RGN) Certification, marking Italy’s first bakery brand to introduce a cookie certified with 100% regenerative soft wheat flour.1 The certification provides independent verification of regenerative outcomes and will be communicated on-pack via the FoodChain ID RGN mark, helping consumers identify products sourced from farms advancing soil health, biodiversity and climate resilience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013488950/en/

FoodChain ID today announced that Mulino Bianco’s Buongrano has been certified to the FoodChain ID Regenerative Agriculture (RGN) Certification, marking Italy’s first bakery brand to introduce a cookie certified with 100% regenerative soft wheat flour.

FoodChain ID’s Regenerative Agriculture Certification is a globally applicable, outcome-based certification aligned with ISO 17065 principles, with options to ensure traceability to market. The certification framework promotes agriculture practices that restore degraded soils, support biodiversity, sequester carbon and build climate resilience. By certifying Buongrano’s soft wheat flour to RGN, Mulino Bianco adds independent assurance to its regenerative commitments ‒ making progress transparent and traceable.

The Buongrano project launched in 2018 as part of La Carta del Mulino, the brand’s code of practice for sustainable soft wheat cultivation, with goals for product quality, biodiversity protection and fair recognition of farmers’ work. Seven years later, the biscuit returns to consumers with a new identity for environmental impact: 100% regenerative soft wheat flour certified to FoodChain ID’s internationally recognized, outcome-based Regenerative Agriculture Certification. Mulino Bianco has committed to extend regenerative soft wheat flours across all product categories by 2030.

“We are honored that Buongrano’s soft wheat flour is certified under our Regenerative Agriculture Certification (RGN). For nearly 30 years, FoodChain ID has helped brands and producers translate sustainability intent into credible, verifiable results ‒ from farm to finished product. RGN’s outcome-based approach gives companies the confidence to scale regenerative practices, substantiate claims, and connect their efforts to climate-finance pathways,” said Dr. Chetan Parmar, Senior Vice President of Technical Services for Europe and Asia.

About FoodChain ID

FoodChain ID is a trusted provider to over 30,000 companies across the global supply chain. The company delivers technology-enabled solutions and technical expertise to keep the food supply chain safe, compliant and transparent. Service areas include product development, regulatory compliance, food safety certification, product certification and testing. Visit www.FoodChainID.com for more information.

1 The first cookie in Italy certified with 100% soft wheat flour from regenerative agriculture as per Mulino Bianco’s company materials.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013488950/en/

Contacts

Media Contact
Ceci Snyder
FoodChain ID
csnyder@foodchainid.com
+1 515-491-5173

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye